Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

Launched by BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE · Jun 11, 2010

Keywords

ClinConnect Summary

Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended larg...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patient (≥ 18 years)
• • patient hospitalized
• • patient receives systemic antibiotic treatment
• • patient contractually capable
• • patient able to follow study procedures
• • informed consent of patient
• Exclusion Criteria:
• • allergy against yeast and/or Perenterol® forte und/oder placebos containing Saccharomyces cerevisiae HANSEN CBS 5926, lactose-monohydrate, magnesium stearate, gelatine, sodium dodecyl sulfate, titan dioxide, microcrystalline cellulose.
• • central venous catheter
• • immunosuppression
• • diarrhoea and/or chronic diarrhoea
• • regular intake of Perenterol®, Perenterol® forte oder Yomogi® in the last seven days before the start of the study
• • systemic antimycotic treatment
• • systemic antibiotic treatment within the last 6 weeks
• • no protection against conception, pregnancy, or lactation
• • simultaneous participation in other clinical trials